Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296320 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of MEDI4893
A Phase 2 study of Staphylococcus Aureus Pneumonia, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
- 20
- Study locations
NCT02296320 is a Phase 2 study of Staphylococcus Aureus Pneumonia that has completed, run by MedImmune. The registered enrollment target is 213 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT02296320, a Phase 2 study of Staphylococcus Aureus Pneumonia, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
- 20
- Study locations
Study Summary
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MEDI4893
Study Locations (20)
Other
- Research Site - Arlon
- Research Site - Brussels
- Research Site - La Louvière
- Research Site - Lodelinsart
- Research Site - Yvoir
- Research Site - Brno
- Research Site - Děčín
- Research Site - Kyjov
- Research Site - Prague
- Research Site - Teplice
- Research Site - Angers
- Research Site - Clermont-Ferrand
- Research Site - Garches
- Research Site - Grenoble
- Research Site - Le Chesnay
- Research Site - Lille
- Research Site - Limoges
- Research Site - Lyon
Georgia
- Research Site - Atlanta
Michigan
- Research Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2014-10-10 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296320
The ClinicalTrials.gov registry entry for NCT02296320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcus Aureus Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02296320 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT02296320 about?
NCT02296320 is a clinical study titled "Study of the Efficacy and Safety of MEDI4893". Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
What is the current status of trial NCT02296320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2014-10-10. Estimated completion is 2018-10-02.
What conditions does trial NCT02296320 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Pneumonia.
What interventions are being tested in trial NCT02296320?
The interventions under investigation include: Placebo (OTHER), MEDI4893 (DRUG).
Who is sponsoring clinical trial NCT02296320?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296320 being conducted?
This trial has 20 study locations across Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.